U.S. Food and Drug Administration Grants Second Approval for EPKINLY® (epcoritamab-bysp) to Treat Patients with Relapsed or Refractory Follicular Lymphoma ...Middle East

- EPKINLY is now the first and only bispecific antibody approved in the U.S. to treat both relapsed or refractory (R/R) follicular lymphoma (FL) and R/R diffuse large B-cell lymphoma (DLBCL) - Bispecific antibodies are designed to induce targeted cell killing by engaging the immune system...

Hence then, the article about u s food and drug administration grants second approval for epkinly epcoritamab bysp to treat patients with relapsed or refractory follicular lymphoma was published today ( Thursday 27/06/2024 - 02:05 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( U.S. Food and Drug Administration Grants Second Approval for EPKINLY® (epcoritamab-bysp) to Treat Patients with Relapsed or Refractory Follicular Lymphoma )

Also on site :

• South Africa pushes for renewable energy investment
• Zelensky is ‘a man in a desperate position’ – Orban
• SeaWorld in Texas Is Opening a First-of-Its-Kind Inverted Coaster This Spring